| Record Information |
|---|
| Version | 5.0 |
|---|
| Status | Expected but not Quantified |
|---|
| Creation Date | 2012-09-06 15:16:49 UTC |
|---|
| Update Date | 2022-03-07 02:51:38 UTC |
|---|
| HMDB ID | HMDB0014462 |
|---|
| Secondary Accession Numbers | |
|---|
| Metabolite Identification |
|---|
| Common Name | Gefitinib |
|---|
| Description | Gefitinib, also known as iressa or ZD 1839, belongs to the class of organic compounds known as quinazolinamines. These are heterocyclic aromatic compounds containing a quianazoline moiety substituted by one or more amine groups. This leads to inappropriate activation of the anti-apoptotic Ras signalling cascade, eventually leading to uncontrolled cell proliferation. Gefitinib is a drug which is used for the continued treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of either platinum-based or docetaxel chemotherapies. Adverse drug reactions (ADRs) are acceptable for a potentially fatal disease. Gefitinib is a very strong basic compound (based on its pKa). In humans, gefitinib is involved in gefitinib action pathway. IPASS (IRESSA Pan-Asia Study) was a randomized, large-scale, double-blinded study which compared gefitinib vs. carboplatin/ paclitaxel as a first-line treatment in advanced NSCLC.IPASS studied 1,217 patients with confirmed adenocarcinoma histology who were former or never smokers. |
|---|
| Structure | COC1=C(OCCCN2CCOCC2)C=C2C(NC3=CC(Cl)=C(F)C=C3)=NC=NC2=C1 InChI=1S/C22H24ClFN4O3/c1-29-20-13-19-16(12-21(20)31-8-2-5-28-6-9-30-10-7-28)22(26-14-25-19)27-15-3-4-18(24)17(23)11-15/h3-4,11-14H,2,5-10H2,1H3,(H,25,26,27) |
|---|
| Synonyms | | Value | Source |
|---|
| 4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline | ChEBI | | Gefitinibum | ChEBI | | Iressa | ChEBI | | Irressat | ChEBI | | N-(3-Chloro-4-fluorophenyl)-7-methoxy-6-(3-(4-morpholinyl)propoxy)-4-quinazolinamine | ChEBI | | ZD 1839 | ChEBI | | ZD-1839 | ChEBI | | ZD1839 | ChEBI | | N-(3-Chloro-4-fluorophenyl)-7-methoxy-6-(3-(4-morpholinyl)propoxy)-4-quinazolinamide | HMDB |
|
|---|
| Chemical Formula | C22H24ClFN4O3 |
|---|
| Average Molecular Weight | 446.902 |
|---|
| Monoisotopic Molecular Weight | 446.152096566 |
|---|
| IUPAC Name | N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(morpholin-4-yl)propoxy]quinazolin-4-amine |
|---|
| Traditional Name | gefitinib |
|---|
| CAS Registry Number | 184475-35-2 |
|---|
| SMILES | COC1=C(OCCCN2CCOCC2)C=C2C(NC3=CC(Cl)=C(F)C=C3)=NC=NC2=C1 |
|---|
| InChI Identifier | InChI=1S/C22H24ClFN4O3/c1-29-20-13-19-16(12-21(20)31-8-2-5-28-6-9-30-10-7-28)22(26-14-25-19)27-15-3-4-18(24)17(23)11-15/h3-4,11-14H,2,5-10H2,1H3,(H,25,26,27) |
|---|
| InChI Key | XGALLCVXEZPNRQ-UHFFFAOYSA-N |
|---|
| Chemical Taxonomy |
|---|
| Description | Belongs to the class of organic compounds known as quinazolinamines. These are heterocyclic aromatic compounds containing a quianazoline moiety substituted by one or more amine groups. |
|---|
| Kingdom | Organic compounds |
|---|
| Super Class | Organoheterocyclic compounds |
|---|
| Class | Diazanaphthalenes |
|---|
| Sub Class | Benzodiazines |
|---|
| Direct Parent | Quinazolinamines |
|---|
| Alternative Parents | |
|---|
| Substituents | - Quinazolinamine
- Anisole
- Aniline or substituted anilines
- Alkyl aryl ether
- Aminopyrimidine
- Chlorobenzene
- Fluorobenzene
- Halobenzene
- Aryl chloride
- Aryl fluoride
- Aryl halide
- Monocyclic benzene moiety
- Morpholine
- Oxazinane
- Pyrimidine
- Benzenoid
- Imidolactam
- Heteroaromatic compound
- Tertiary aliphatic amine
- Tertiary amine
- Secondary amine
- Azacycle
- Dialkyl ether
- Ether
- Oxacycle
- Organonitrogen compound
- Hydrocarbon derivative
- Organooxygen compound
- Organic nitrogen compound
- Amine
- Organic oxygen compound
- Organofluoride
- Organochloride
- Organopnictogen compound
- Organohalogen compound
- Aromatic heteropolycyclic compound
|
|---|
| Molecular Framework | Aromatic heteropolycyclic compounds |
|---|
| External Descriptors | |
|---|
| Ontology |
|---|
| Not Available | Not Available |
|---|
| Physical Properties |
|---|
| State | Solid |
|---|
| Experimental Molecular Properties | | Property | Value | Reference |
|---|
| Melting Point | Not Available | Not Available | | Boiling Point | Not Available | Not Available | | Water Solubility | 0.027 g/L | Not Available | | LogP | 3.2 | Not Available |
|
|---|
| Experimental Chromatographic Properties | Not Available |
|---|
| Predicted Molecular Properties | |
|---|
| Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredicted Retention Times Underivatized| Chromatographic Method | Retention Time | Reference |
|---|
| Measured using a Waters Acquity ultraperformance liquid chromatography (UPLC) ethylene-bridged hybrid (BEH) C18 column (100 mm × 2.1 mm; 1.7 μmparticle diameter). Predicted by Afia on May 17, 2022. Predicted by Afia on May 17, 2022. | 4.39 minutes | 32390414 | | Predicted by Siyang on May 30, 2022 | 10.6028 minutes | 33406817 | | Predicted by Siyang using ReTip algorithm on June 8, 2022 | 2.9 minutes | 32390414 | | AjsUoB = Accucore 150 Amide HILIC with 10mM Ammonium Formate, 0.1% Formic Acid | 40.8 seconds | 40023050 | | Fem_Long = Waters ACQUITY UPLC HSS T3 C18 with Water:MeOH and 0.1% Formic Acid | 1898.6 seconds | 40023050 | | Fem_Lipids = Ascentis Express C18 with (60:40 water:ACN):(90:10 IPA:ACN) and 10mM NH4COOH + 0.1% Formic Acid | 178.0 seconds | 40023050 | | Life_Old = Waters ACQUITY UPLC BEH C18 with Water:(20:80 acetone:ACN) and 0.1% Formic Acid | 173.1 seconds | 40023050 | | Life_New = RP Waters ACQUITY UPLC HSS T3 C18 with Water:(30:70 MeOH:ACN) and 0.1% Formic Acid | 165.5 seconds | 40023050 | | RIKEN = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 114.5 seconds | 40023050 | | Eawag_XBridgeC18 = XBridge C18 3.5u 2.1x50 mm with Water:MeOH and 0.1% Formic Acid | 426.9 seconds | 40023050 | | BfG_NTS_RP1 =Agilent Zorbax Eclipse Plus C18 (2.1 mm x 150 mm, 3.5 um) with Water:ACN and 0.1% Formic Acid | 402.3 seconds | 40023050 | | HILIC_BDD_2 = Merck SeQuant ZIC-HILIC with ACN(0.1% formic acid):water(16 mM ammonium formate) | 333.7 seconds | 40023050 | | UniToyama_Atlantis = RP Waters Atlantis T3 (2.1 x 150 mm, 5 um) with ACN:Water and 0.1% Formic Acid | 787.9 seconds | 40023050 | | BDD_C18 = Hypersil Gold 1.9µm C18 with Water:ACN and 0.1% Formic Acid | 348.3 seconds | 40023050 | | UFZ_Phenomenex = Kinetex Core-Shell C18 2.6 um, 3.0 x 100 mm, Phenomenex with Water:MeOH and 0.1% Formic Acid | 1224.2 seconds | 40023050 | | SNU_RIKEN_POS = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 283.5 seconds | 40023050 | | RPMMFDA = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 270.5 seconds | 40023050 | | MTBLS87 = Merck SeQuant ZIC-pHILIC column with ACN:Water and :ammonium carbonate | 242.4 seconds | 40023050 | | KI_GIAR_zic_HILIC_pH2_7 = Merck SeQuant ZIC-HILIC with ACN:Water and 0.1% FA | 155.2 seconds | 40023050 | | Meister zic-pHILIC pH9.3 = Merck SeQuant ZIC-pHILIC column with ACN:Water 5mM NH4Ac pH9.3 and 5mM ammonium acetate in water | 9.7 seconds | 40023050 |
Predicted Kovats Retention IndicesUnderivatizedDerivatized| Derivative Name / Structure | SMILES | Kovats RI Value | Column Type | Reference |
|---|
| Gefitinib,1TMS,isomer #1 | COC1=CC2=NC=NC(N(C3=CC=C(F)C(Cl)=C3)[Si](C)(C)C)=C2C=C1OCCCN1CCOCC1 | 3453.5 | Semi standard non polar | 33892256 | | Gefitinib,1TMS,isomer #1 | COC1=CC2=NC=NC(N(C3=CC=C(F)C(Cl)=C3)[Si](C)(C)C)=C2C=C1OCCCN1CCOCC1 | 3391.4 | Standard non polar | 33892256 | | Gefitinib,1TMS,isomer #1 | COC1=CC2=NC=NC(N(C3=CC=C(F)C(Cl)=C3)[Si](C)(C)C)=C2C=C1OCCCN1CCOCC1 | 4893.7 | Standard polar | 33892256 | | Gefitinib,1TBDMS,isomer #1 | COC1=CC2=NC=NC(N(C3=CC=C(F)C(Cl)=C3)[Si](C)(C)C(C)(C)C)=C2C=C1OCCCN1CCOCC1 | 3644.1 | Semi standard non polar | 33892256 | | Gefitinib,1TBDMS,isomer #1 | COC1=CC2=NC=NC(N(C3=CC=C(F)C(Cl)=C3)[Si](C)(C)C(C)(C)C)=C2C=C1OCCCN1CCOCC1 | 3566.6 | Standard non polar | 33892256 | | Gefitinib,1TBDMS,isomer #1 | COC1=CC2=NC=NC(N(C3=CC=C(F)C(Cl)=C3)[Si](C)(C)C(C)(C)C)=C2C=C1OCCCN1CCOCC1 | 4869.5 | Standard polar | 33892256 |
|
|---|
| GC-MS Spectra| Spectrum Type | Description | Splash Key | Deposition Date | Source | View |
|---|
| Predicted GC-MS | Predicted GC-MS Spectrum - Gefitinib GC-MS (Non-derivatized) - 70eV, Positive | splash10-0uxr-9424700000-182dba69c82bee61cbe2 | 2017-09-01 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - Gefitinib GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | Wishart Lab | View Spectrum |
MS/MS Spectra| Spectrum Type | Description | Splash Key | Deposition Date | Source | View |
|---|
| Experimental LC-MS/MS | LC-MS/MS Spectrum - Gefitinib LC-ESI-qTof , Positive-QTOF | splash10-0002-1511900000-d0570bedf59699989575 | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Gefitinib , positive-QTOF | splash10-00di-0193000000-38bb088cc8af6a0e12a4 | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Gefitinib , positive-QTOF | splash10-0002-1511900000-d0570bedf59699989575 | 2017-09-14 | HMDB team, MONA | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Gefitinib 10V, Positive-QTOF | splash10-0002-0201900000-dafa6866c6b59a71a89e | 2016-08-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Gefitinib 20V, Positive-QTOF | splash10-0udi-2904200000-011d82a75223a5017b87 | 2016-08-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Gefitinib 40V, Positive-QTOF | splash10-009l-9402000000-d87048e0478c6d231bfe | 2016-08-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Gefitinib 10V, Negative-QTOF | splash10-0002-0004900000-bb4c9a2e360df1c7e52e | 2016-08-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Gefitinib 20V, Negative-QTOF | splash10-014s-3019400000-c4f741a0f46f6e8edd9f | 2016-08-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Gefitinib 40V, Negative-QTOF | splash10-0uy0-3279000000-593bcb0bda5ac3068617 | 2016-08-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Gefitinib 10V, Negative-QTOF | splash10-0002-0000900000-f5b40d44879371ef81fb | 2021-09-22 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Gefitinib 20V, Negative-QTOF | splash10-0f6t-0005900000-a102859e7a71e3a4e883 | 2021-09-22 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Gefitinib 40V, Negative-QTOF | splash10-0udi-1029000000-4b9f808b7f687fe38a43 | 2021-09-22 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Gefitinib 10V, Positive-QTOF | splash10-0002-0000900000-fc203d826511c11b8cd1 | 2021-09-22 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Gefitinib 20V, Positive-QTOF | splash10-0fba-1901400000-c8c0d48bbd64a7e7fa9a | 2021-09-22 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Gefitinib 40V, Positive-QTOF | splash10-0uk9-9515200000-6abbaa993868c8b744f4 | 2021-09-22 | Wishart Lab | View Spectrum |
|
|---|
| General References | - Sordella R, Bell DW, Haber DA, Settleman J: Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science. 2004 Aug 20;305(5687):1163-7. Epub 2004 Jul 29. [PubMed:15284455 ]
- Pao W, Miller V, Zakowski M, Doherty J, Politi K, Sarkaria I, Singh B, Heelan R, Rusch V, Fulton L, Mardis E, Kupfer D, Wilson R, Kris M, Varmus H: EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A. 2004 Sep 7;101(36):13306-11. Epub 2004 Aug 25. [PubMed:15329413 ]
- (). FDA label . .
|
|---|